Sigma Healthcare Shares Initiated Neutral, as Analyst See’s Downside

RBC Capital has launched coverage of Sigma Healthcare shares (ASX: SIG) with a cautious stance, setting a price target that implies further downside for the ASX-listed pharmaceutical distributor despite its transformational merger with Chemist Warehouse.

Sigma Healthcare shares head into Tuesday’s open at A$2.66, already down 9.5 percent%, yet analyst Michael Toner’s Sector Perform rating carries a A$2.50 price target, suggesting another 6% of potential decline. The initiation marks a sobering assessment of a stock that has captured significant attention following one of the largest corporate combinations in Australian healthcare history.

RBC’s neutral positioning centres on two key concerns: the risks embedded in Sigma’s early-stage international expansion ambitions and a valuation that already reflects much of the merger upside. The call arrives at a delicate moment for the company, which has recently upgraded its FY25 normalised EBIT guidance to A$64–70 million from a prior range of A$50–60 million, demonstrating operational momentum even as markets question whether the share price has run ahead of fundamentals.

The Chemist Warehouse merger, completed through one of the largest share issuances in ASX history, has fundamentally reshaped Sigma’s business model. The combined entity now wields substantially greater scale in pharmaceutical distribution and retail, with improved buying power and the potential for meaningful cost synergies. Management’s confidence in raising earnings guidance mid-year underscores that integration is proceeding more smoothly than some had feared.

Yet the very factors that make the merger strategically compelling also introduce complexity that justifies caution. The enlarged group faces heightened regulatory scrutiny around pharmacy ownership structures, a reality that has already drawn ASX attention regarding unusual trading activity. Any future policy shifts affecting PBS remuneration or competitive dynamics could disproportionately impact the market leader.

International expansion, flagged by management as a key growth avenue, represents both opportunity and execution risk. While the Chemist Warehouse brand enjoys strong recognition domestically, replicating that success offshore requires substantial capital investment with uncertain payback periods. RBC’s emphasis on this risk suggests the firm sees management’s offshore ambitions as more likely to dilute returns than drive meaningful value creation in the near term.

The company’s recent partnership with a major pharmacy chain, expected to deliver approximately 10 percent revenue uplift in 2025, demonstrates Sigma’s ability to broaden its distribution network beyond the Chemist Warehouse ecosystem. This diversification strengthens the bull case for sustainable growth, though it also raises questions about margin pressure if contracts are priced aggressively to win scale.

From a valuation perspective, the stock’s performance reflects a market that has already capitalised much of the good news. The sharp re-rating following merger completion and subsequent guidance upgrades has left less room for positive surprises. With a Sector Perform rating, RBC is effectively signalling that risk and reward are now balanced at best, a marked shift from the more optimistic positioning that characterised earlier stages of the merger narrative.

Sigma Healthcare now finds itself in the challenging position of having executed a transformational deal successfully enough to drive a strong share price response, yet not dramatically enough to overcome valuation scepticism from new coverage. Now the next move could depend on management’s ability to deliver on integration promises, and demonstrate that international ambitions can be pursued without sacrificing returns.